Io Biotech Inc (IOBT) Stock Price, Quote & News

Company Profile

IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead therapeutic cancer vaccine candidate includes IO102-IO103, which targets cancer cells and immune-suppressive cells in the tumor microenvironment that express indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to...

Industry: Biotechnology

Sector: Healthcare

Phone: 45 70 70 29 80

Website: www.iobiotech.com

Address:

Ole MaalOees Vej 3, Copenhagen N, Copenhagen, Denmark

highnihilism Oct. 4 at 8:58 AM

0 · Reply

GCPA Oct. 3 at 10:40 PM

$IOBT While we reach ESMO (and some data and some clarification about the future). They could not be unaware of: - Pretreated responding very bad (the results of Phase 1/2 were clear). - They enrolled just 17 (4% of the whole population) USA patients. First question that was asked in August 11 presentation was about the implications of that. - Trial was underpowered. We all know that, with just 20 events more for Primary analysis, p-value was going to be right. So, well. They tried, and may be an EMA submission is still possible (some relief, no doubt). But bottom line is that they were conducting a well crowded exploratory Phase 2.

1 · Reply

TraderJay85 Oct. 3 at 8:13 PM

$DKI small win. went to 1.29 $IOBT holding $BNAI went to .69 🔥 $RUM went to 8.95 🔥 $QCLS went to 6.95 🔥

0 · Reply

RobertMccartney942 Oct. 3 at 4:22 PM

$IOBT is building forward. FDCT’s $532M+ funds under advice reflect strong foundations and trusted financial performance.

1 · Reply

Amcollins711 Oct. 3 at 3:55 PM

$IOBT So do we load the cheapies before they announce success of IO102-IO103 + KEYTRUDA (pembrolizumab) during the 10/17 conference in Germany?

0 · Reply

BadyBady Oct. 3 at 3:43 PM

$IOBT Close 0.48+ will see 0.70

0 · Reply

badprecog Oct. 3 at 2:36 PM

$IOBT EMA leak?

0 · Reply

Sohrab1 Oct. 3 at 1:12 PM

$IOBT buy

0 · Reply

no2197 Oct. 3 at 12:21 PM

$IOBT

1 · Reply

SuperNovaBank Oct. 3 at 5:25 AM

Top watch: GIPR The intrinsic value for GIPR is pegged at $13.53+ per share 🚀 — compare that to current levels 👀 and you’ll see just how MASSIVELY undervalued this play is. With the strategic alternatives process in motion (Cantor Fitzgerald onboard, potential merger, sale, or recap), the upside potential here is unreal. This isn’t just speculation — the numbers are CLEAR 📊. GIPR is trading at a deep discount to its real worth. Smart money will catch on fast. Don’t sleep on this one. 🚨📈 $CLPT $PHOE $IOBT $DBVT watching

0 · Reply

IO Biotech Provides Update Following Pre-BLA Meeting with FDA

Sep 23, 2025, 8:05 AM EDT - 11 days ago

IO Biotech Announces Late-Breaking Abstract in Advanced Melanoma Selected for Oral Presentation at ESMO Congress 2025

Sep 9, 2025, 11:41 AM EDT - 25 days ago

IO Biotech, Inc. (IOBT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 4, 2025, 8:05 AM EDT - 4 weeks ago

IO Biotech Announces Participation in Upcoming Investor Conferences

Aug 14, 2025, 4:05 PM EDT - 7 weeks ago

IO Biotech Reports Second Quarter 2025 Financial Results and Provides Business Highlights

Aug 12, 2025, 4:17 PM EDT - 7 weeks ago

IO Biotech: A Buying Opportunity Following Phase 3 Readout In Melanoma

Aug 11, 2025, 8:24 AM EDT - 7 weeks ago

IO Biotech's cancer vaccine shows improvement in late-stage study goal

Aug 11, 2025, 8:00 AM EDT - 7 weeks ago

IO Biotech Announces Clinical Improvement in Progression Free Survival Demonstrated in Pivotal Phase 3 Trial of Cylembio® plus KEYTRUDA® (Pembrolizumab) for the Treatment of First-line Advanced Melanoma, but Statistical Significance Narrowly Missed

Aug 10, 2025, 8:00 AM EDT - 7 weeks ago

IO Biotech to Announce Topline Results of Pivotal Phase 3 Trial of Cylembio® in Combination with KEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma

May 20, 2025, 8:05 AM EDT - 4 months ago

IO Biotech Announces Participation in Cowen 6th Annual Oncology Innovation Summit and Jefferies Global Healthcare Conference

May 14, 2025, 8:05 AM EDT - 5 months ago

IO Biotech Reports First Quarter 2025 Financial Results and Business Highlights

Apr 26, 2025, 3:05 PM EDT - 5 months ago

IO Biotech Showcases Scientific Leadership Through Cancer Vaccines Educational Session at the American Association for Cancer Research (AACR) Annual Meeting 2025

Apr 25, 2025, 1:00 PM EDT - 5 months ago

IO Biotech Presents New Data at AACR 2025 Supporting Dual Mechanism and Immune Activation of Cancer Vaccines IO102-IO103 and IO170

Mar 25, 2025, 4:35 PM EDT - 6 months ago

IO Biotech Announces Acceptance of Abstracts to be Presented at the 2025 American Association for Cancer Research (AACR) Annual Meeting

Mar 18, 2025, 8:00 AM EDT - 7 months ago

IO Biotech Named Among Fast Company's World's Most Innovative Companies of 2025

Mar 4, 2025, 4:17 PM EST - 7 months ago

IO Biotech Reports 2024 Business Highlights

Feb 23, 2025, 12:07 PM EST - 7 months ago

IO Biotech Announces New Preclinical Data for Additional Pipeline Candidate Presented at the AACR-IO Conference

Feb 20, 2025, 8:05 AM EST - 8 months ago

IO Biotech to Present at the 45th Annual Cowen Health Care Conference

Feb 4, 2025, 8:05 AM EST - 8 months ago

IO Biotech Announces Publication of Preclinical Data Investigating Immune-Modulatory Effects of IO112, an Arginase 1-Targeting Therapeutic Cancer Vaccine Candidate

Jan 9, 2025, 8:05 AM EST - 9 months ago

IO Biotech Completes Enrollment in Phase 2 Trial of its Investigational, Off-the-shelf Therapeutic Cancer Vaccine, IO102-IO103, as Neoadjuvant/Adjuvant Treatment for Patients with Resectable Melanoma or Head and Neck Cancer

Dec 20, 2024, 8:05 AM EST - 10 months ago

IO Biotech secures up to €57.5 million in debt financing from the European Investment Bank

Nov 12, 2024, 7:05 AM EST - 11 months ago

IO Biotech Reports Third Quarter 2024 Financial Results and Provides Business Highlights

Nov 7, 2024, 10:00 AM EST - 11 months ago

IO Biotech Reports its Off-the-Shelf Therapeutic Cancer Vaccine, IO102-IO103, in Combination with KEYTRUDA® Demonstrates Promising Activity and Durability in First-line Treatment of Patients with Metastatic Lung Cancer in Phase 2 IOB-022 Study

Oct 4, 2024, 9:00 AM EDT - 1 year ago

IO Biotech Announces Two Poster Presentations at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting

Sep 14, 2024, 2:30 AM EDT - 1 year ago

IO Biotech Announces Positive Results from Phase 2 Trial of IO102-IO103 in the First-line Treatment of Advanced Head and Neck Cancer

Aug 30, 2024, 4:05 PM EDT - 1 year ago

IO Biotech Updates on Pivotal Phase 3 Trial of IO102-IO103 in Combination with KEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma

Aug 13, 2024, 7:05 AM EDT - 1 year ago

IO Biotech Reports Second Quarter 2024 Financial Results and Provides Business Highlights

Jul 25, 2024, 4:05 PM EDT - 1 year ago

IO Biotech Announces New Head and Neck Cohort Data Accepted for Presentation at ESMO Congress 2024

May 23, 2024, 8:30 AM EDT - 1 year ago

IO Biotech to Present at Jefferies Global Healthcare Conference

May 14, 2024, 7:55 AM EDT - 1 year ago

IO Biotech Reports First Quarter 2024 Financial Results and Provides Business Highlights

Apr 24, 2024, 4:30 PM EDT - 1 year ago

IO Biotech Announces Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 15, 2024, 8:30 AM EDT - 1 year ago

IO Biotech Expands Senior Leadership Team to Progress Commercialization Readiness

Apr 9, 2024, 12:00 PM EDT - 1 year ago

IO Biotech Presents New Data at AACR 2024 Further Supporting Dual Mechanism of Action of Lead Cancer Vaccine, IO102-IO103

Apr 5, 2024, 8:30 AM EDT - 1 year ago

IO Biotech Appoints Faiçal Miyara, Ph.D., as Chief Business Officer

Mar 6, 2024, 4:11 PM EST - 1 year ago

IO Biotech Announces Acceptance of Abstract to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Mar 5, 2024, 4:40 PM EST - 1 year ago

IO Biotech Announces 2023 Fourth-Quarter and Year-End Results

Feb 26, 2024, 4:05 PM EST - 1 year ago

IO Biotech to Present at 44th Annual Cowen Health Care Conference

Jan 3, 2024, 3:04 AM EST - 1 year ago

IO Biotech: A Phase 3 Company Getting No Respect

Dec 21, 2023, 8:30 AM EST - 1 year ago

IO Biotech Announces First Patient Dosed in Phase 2 Neoadjuvant/Adjuvant Solid Tumor Basket Trial

Nov 13, 2023, 8:12 AM EST - 2 years ago

IO Biotech Announces 2023 Third Quarter Results

Nov 13, 2023, 8:00 AM EST - 2 years ago

IO Biotech Appoints Helen Collins, MD, to its Board of Directors

Nov 10, 2023, 8:00 AM EST - 2 years ago

IO Biotech Completes Enrollment of 380 Patients in Pivotal Phase 3 Trial in Advanced Melanoma

Nov 1, 2023, 8:30 AM EDT - 2 years ago

IO Biotech Presents Three Posters at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

Oct 23, 2023, 1:00 AM EDT - 2 years ago

Encouraging Preliminary Data from a Phase 2 Trial Evaluating IO102-IO103 in Combination with Pembrolizumab for First-line Treatment of Patients with Non-small Cell Lung Cancer and Squamous Cell Carcinoma of the Head and Neck Presented at the European Soci

Oct 3, 2023, 4:30 PM EDT - 2 years ago

IO Biotech Announces Three Poster Presentations at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

Sep 12, 2023, 8:05 AM EDT - 2 years ago

IO Biotech Announces New Data Related to its IO102-IO103 Therapeutic Cancer Vaccine Presented Today at the IASLC 2023 World Conference on Lung Cancer

Aug 11, 2023, 8:30 AM EDT - 2 years ago

IO Biotech Announces 2023 Second Quarter Results

Aug 11, 2023, 8:05 AM EDT - 2 years ago

IO Biotech Appoints Heidi Hunter to its Board of Directors

Aug 8, 2023, 8:05 AM EDT - 2 years ago

IO Biotech Announces Abstract Accepted for Poster Presentation at ESMO Congress 2023

Aug 7, 2023, 8:30 AM EDT - 2 years ago

IO Biotech, Inc. Announces $75 Million Private Placement Financing

highnihilism Oct. 4 at 8:58 AM

0 · Reply

GCPA Oct. 3 at 10:40 PM

1 · Reply

TraderJay85 Oct. 3 at 8:13 PM

$DKI small win. went to 1.29 $IOBT holding $BNAI went to .69 🔥 $RUM went to 8.95 🔥 $QCLS went to 6.95 🔥

0 · Reply

RobertMccartney942 Oct. 3 at 4:22 PM

$IOBT is building forward. FDCT’s $532M+ funds under advice reflect strong foundations and trusted financial performance.

1 · Reply

Amcollins711 Oct. 3 at 3:55 PM

$IOBT So do we load the cheapies before they announce success of IO102-IO103 + KEYTRUDA (pembrolizumab) during the 10/17 conference in Germany?

0 · Reply

BadyBady Oct. 3 at 3:43 PM

$IOBT Close 0.48+ will see 0.70

0 · Reply

badprecog Oct. 3 at 2:36 PM

$IOBT EMA leak?

0 · Reply

Sohrab1 Oct. 3 at 1:12 PM

$IOBT buy

0 · Reply

no2197 Oct. 3 at 12:21 PM

$IOBT

1 · Reply

SuperNovaBank Oct. 3 at 5:25 AM

0 · Reply

TraderJay85 Oct. 3 at 12:01 AM

PRE-MARKET MOVERS (PMM) Last nights PMM we hit 15 out of 18. Other 3 still playable above stop. $DKI 1.07 Stop $IOBT .45 $BNAI .40 $RUM 8.15 $QCLS 5.53 Never hold under support. if it goes below then sell. Jump back in if it comes back to last support like YDES. NO EMAILS NO DISCORDS JUST FREE IDEAS TO EVERYONE. HIT THE FOLLOW AND LETS MAKE MONEY TOGETHER ❤️

0 · Reply

badprecog Oct. 2 at 9:38 PM

$IOBT $186 million in R&D Costs to date...

0 · Reply

smoketuna Oct. 2 at 8:46 PM

After Hours runners! 🎯 TunaSignal.ai - Catch the Big Movers Before They Break Out - Powered by AI #DayTrading #Investing #Stock #StockMarket $MIGI $RVPH $IOBT $TRON $ABVE

0 · Reply

MexaTraders Oct. 2 at 8:32 PM

Big traders are on ticker ASTC now.. its breaking out.. @TopStockAlerts has over 100,000 Followers on Stocktwits and is on ASTC now! Breaking out now.. ASTC has only 600k shares outstanding People from $IOBT $TMNG $NVNI $STSS are moving to ASTC now. !

0 · Reply

GCPA Oct. 2 at 8:11 PM

$IOBT Dead cat bounce? Let's see volume tomorrow. Days with highest volume so far: Aug. 11: 82.9 mill shares (down) Aug. 15: 37.9 mill shares (up) Sept. 29: 36.7 mill shares (down) Octb. 02: 16.4 mill shares (up)

0 · Reply

no2197 Oct. 2 at 7:04 PM

$IOBT power hour let’s do it!

0 · Reply

99DegreesInvestments Oct. 2 at 6:19 PM

$ANGX $CURX $IOBT $QQQ $SPY are we in a bull market yet, when is it supposed to come?

0 · Reply

Sohrab1 Oct. 2 at 3:52 PM

$IOBT is trading below cash value.

1 · Reply

GCPA Oct. 2 at 3:35 PM

$IOBT Today this thing can close above 0.50. Ideas about what hands are doing it? Days with highest volume so far: VOL: August 11: 82.9 mill shares (down) August 15: 37.9 mill shares (up) Sept 29: 36.7 mill shares (down) Octob. 02: 10 mill shares at 11:30.

0 · Reply

BOUDIN420 Oct. 2 at 3:30 PM

$IOBT

0 · Reply

badprecog Oct. 2 at 3:14 PM

$IOBT Dr. Z originally stated that they were going to submit a BLA with the EMA this year, and then moved it back to early next year when she thought she was submitting to the FDA this year. So EMA timeframe is likely moved up quite a bit, if they are going to file a BLA with EMA to this year. Their process usually takes a year unless you have special status with them.

0 · Reply

outlawinvestor1 Oct. 2 at 3:13 PM

$IOBT correction: this trial was a randomized open label controlled trial. it was a well designed trial, given soc, when the trial began. fda was shortsighted in their decision imho.

0 · Reply

Market Cap	31.75M
Revenue (ttm)	0.00
Net Income (ttm)	-95.49M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	4.23

Volume	5,573,300
Avg Vol	5,404,680
Day's Range	N/A - N/A
Shares Out	65.88M
Stochastic %K	12%
Beta	0.21
Analysts	Sell
Price Target	$4.80